Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442% % -21%
Debt-to-equity 63% % 2.9%
Return On Equity 8.3% %
Return On Assets 5.1% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65,117,761 shares
Common Stock, Shares, Outstanding 61,790,239 shares 0.67%
Entity Public Float $199,000,000 USD -15%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 82,397,753 shares 0.47%
Weighted Average Number of Shares Outstanding, Diluted 82,397,753 shares 0.47%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $138,387,000 USD 26%
General and Administrative Expense $34,640,000 USD 1.5%
Operating Income (Loss) $8,511,000 USD -24%
Nonoperating Income (Expense) $13,443,000 USD 35%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $21,954,000 USD -27%
Income Tax Expense (Benefit) $1,008,000 USD 162%
Net Income (Loss) Attributable to Parent $20,946,000 USD -14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $208,343,000 USD 66%
Cash, Cash Equivalents, and Short-term Investments $391,300,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $9,000,000 USD
Assets, Current $401,817,000 USD 60%
Property, Plant and Equipment, Net $27,598,000 USD -12%
Operating Lease, Right-of-Use Asset $25,065,000 USD -8.4%
Other Assets, Noncurrent $411,000 USD 158%
Assets $459,841,000 USD 46%
Accounts Payable, Current $14,509,000 USD 265%
Employee-related Liabilities, Current $7,260,000 USD 8.3%
Liabilities, Current $61,443,000 USD 48%
Operating Lease, Liability, Noncurrent $35,927,000 USD -10%
Liabilities $214,004,000 USD 95%
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,247,000 USD -40%
Retained Earnings (Accumulated Deficit) $431,079,000 USD 4.6%
Stockholders' Equity Attributable to Parent $245,837,000 USD 20%
Liabilities and Equity $459,841,000 USD 46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $45,492,000 USD -19%
Net Cash Provided by (Used in) Financing Activities $246,000 USD
Net Cash Provided by (Used in) Investing Activities $100,229,000 USD -1117%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 61,790,239 shares 0.67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $145,707,000 USD -419%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $213,293,000 USD 63%
Deferred Tax Assets, Valuation Allowance $72,157,000 USD 32%
Deferred Tax Assets, Gross $83,113,000 USD 25%
Depreciation $8,329,000 USD 5.4%
Payments to Acquire Property, Plant, and Equipment $1,587,000 USD 15%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $20,021,000 USD -15%
Property, Plant and Equipment, Gross $53,122,000 USD 6.8%
Operating Lease, Liability, Current $4,241,000 USD 16%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards $50,002,000 USD 19%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD -100%
Amortization of Intangible Assets $637,000 USD 10%
Deferred Tax Assets, Net of Valuation Allowance $10,956,000 USD -10%
Share-based Payment Arrangement, Expense $19,025,000 USD 1.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%